Active substances

Econazole›

G01AF05 Genito urinary system and sex hormones | Antiinfectives and antiseptics, excl. combinations with corticosteroids | Imidazole derivatives

Indicated for: fungal skin infections

Eculizumab›

L04AJ01 Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Complement inhibitors

Indicated for: complement-mediated disorders

Edetate of sodium and calcium›

V03AB03 Various | All other therapeutic products | All other therapeutic products | Antidotes

Indicated for: lead poisoning

Edoxaban›

B01AF03 Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Direct factor xa inhibitors

Indicated for: prevention and treatment of thromboembolism

Efalizumab›

L04AA21 Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants

Indicated for: psoriasis

Efavirenz›

J05AG03 Antiinfectives for systemic use | Direct acting antivirals | Non-nucleoside reverse transcriptase inhibitors

Indicated for: HIV-1 infection

Efavirenz + emtricitabine + tenofovir›

J05AR06 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Indicated for: HIV-1 infection

Efavirenz + emtricitabine + tenofovir disoproxil›

J05AR06 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Indicated for: HIV-1 infection

Efgartigimod alfa›

L04AA58 Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants

Indicated for: myasthenia gravis

Eflornithine›

D11AX Dermatologicals | Other dermatological preparations | Other dermatological preparations | Other dermatologicals

Indicated for: facial hirsutism; African trypanosomiasis

Efmoroctocog alfa›

B02BD02 Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors

Indicated for: bleeding; coagulation disorders

Eftrenonacog alfa›

B02BD04 Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors

Indicated for: bleeding; coagulation disorders

Elacestrant›

L02BA04 Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-estrogens

Indicated for: breast cancer

Elafibranor›

A05AX06 Alimentary tract and metabolism | Bile therapy | Other drugs for bile therapy

Indicated for: primary biliary cholangitis

Elbasvir + grazoprevir›

J05AP54 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections

Indicated for: chronic hepatitis C

Electrolytes›

B05BB01 Blood and blood forming organs | I.v. solutions | Solutions affecting the electrolyte balance

Indicated for: electrolyte imbalance

Eletriptan›

N02CC06 Nervous system | Antimigraine preparations | Selective serotonin (5HT1) agonists

Indicated for: migraine

Eliglustat›

A16AX10 Alimentary tract and metabolism | Other alimentary tract and metabolism products | Other alimentary tract and metabolism products | Various alimentary tract and metabolism products

Indicated for: Gaucher disease

Elosulfase alfa›

A16AB12 Alimentary tract and metabolism | Other alimentary tract and metabolism products | Other alimentary tract and metabolism products | Enzymes

Indicated for: lysosomal enzyme deficiency

Elranatamab›

L01FX32 Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Other monoclonal antibodies and antibody drug conjugates

Indicated for: hematologic malignancies

Eltrombopag›

B02BX05 Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics

Indicated for: thrombocytopenia

Elvitegravir + cobicistat + emtricitabine + tenofovir›

J05AR18 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Indicated for: HIV-1 infection

Emedastine›

S01GX06 Sensory organs | Decongestants and antiallergics | Other antiallergics

Indicated for: allergic conjunctivitis

Emicizumab›

B02BX06 Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics

Indicated for: hemophilia

Empagliflozin›

A10BK03 Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Indicated for: type 2 diabetes mellitus; heart failure; chronic kidney disease

Empagliflozin + metformin›

A10BD20 Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs

Indicated for: type 2 diabetes mellitus

Emtricitabine›

J05AF09 Antiinfectives for systemic use | Direct acting antivirals | Nucleoside and nucleotide reverse transcriptase inhibitors

Indicated for: HIV-1 infection

Emtricitabine + rilpivirine + tenofovir alafenamide›

J05AR19 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Indicated for: HIV-1 infection

Emtricitabine + tenofovir›

J05AR03 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Indicated for: HIV-1 infection

Emtricitabine + tenofovir alafenamide›

J05AR17 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Indicated for: HIV-1 infection